(Q36431537)

14 August 2017

Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide (English)

1 reference

14 August 2017

W W ten Bokkel Huinink

2

object named as

ten Bokkel Huinink WW

1 reference

14 August 2017

Herben VM

1

1 reference

14 August 2017

Dubbelman AC

3

1 reference

14 August 2017

Mandjes IA

4

1 reference

14 August 2017

Groot Y

5

1 reference

14 August 2017

van Gortel-van Zomeren DM

6

1 reference

14 August 2017

Beijnen JH

7

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 January 1997

1 reference

British Journal of Cancer

14 August 2017

1 reference

14 August 2017

76

1 reference

14 August 2017

11

1 reference

14 August 2017

1500-1508

1 reference

Clinical pharmacokinetics of topotecan

14 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228184

DNA topoisomerase I and II as targets for rational design of new anticancer drugs

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228184

DNA topoisomerase I and II in cancer chemotherapy: update and perspectives

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228184

Prolonged administration of low-dose, infusional etoposide in patients with etoposide-sensitive neoplasms: a phase I/II study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228184

Concepts of synergism and antagonism.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228184

Phase I Clinical and Pharmacology Study of Topotecan Given Daily for 5 Consecutive Days to Patients With Advanced Solid Tumors, With Attempt at Dose Intensification Using Recombinant Granulocyte Colony-Stimulating Factor

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228184

Kinetics of pharmacologic response

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228184

Topoisomerase-targeting antitumor drugs

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228184

Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228184

Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228184

Sequence-dependent modulation of anticancer drug activities by 7-ethyl-10-hydroxycamptothecin in an HST-1 human squamous carcinoma cell line

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228184

Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228184

High-performance liquid chromatographic determination of the novel antitumour drug topotecan and topotecan as the total of the lactone plus carboxylate forms, in human plasma.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228184

Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228184

Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228184

Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228184

Effects of CPT-11 in combination with other anti-cancer agents in culture

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228184

Characterization of camptothecin-resistant chinese hamster lung cells

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228184

Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228184

High-performance liquid chromatographic analysis of the semisynthetic epipodophyllotoxins teniposide and etoposide using electrochemical detection

4 December 2018

1 reference

12 December 2020

1 reference

12 December 2020

A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer

1 reference

12 December 2020

Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons

1 reference

12 December 2020

Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice

1 reference

12 December 2020

Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor

1 reference

12 December 2020

Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.1997.585

1 reference

14 August 2017

1 reference

14 August 2017

PubMed publication ID

9400949

1 reference